Adlai Nortye (ANL): Prakiraan rega marang bathi

Logo grafis Adlai Nortye Ltd (ANL)

The strategic goal of Adlai Nortye Ltd. (ANL) is to achieve financial autonomy through cash reserves, bypassing the influence of GDP. The expected P/E multiple valuation of the company on the GURU.Markets system's dynamic chart captures progress, where the value of 0.00 serves as the current indicator. Barriers include the necessity of developing centers in the US and China, as well as adapting software to global regulatory standards.

Pangali mangsa ngarep rega marang bathi: Adlai Nortye Ltd. (ANL) kanggo 21.02.2024 - 17.11.2026

Rincian analitis perusahaan Adlai Nortye Ltd.

Ringkesan analitik perusahaan:ANL Adlai Nortye Limited
Produk merek Adlai Nortye Limited

The forward P/E assesses the value of Adlai Nortye Ltd. (ANL) shares relative to expected earnings, allowing investors to determine the premium paid for future business growth rates. Analyzing the current forward P/E level of Adlai Nortye Ltd. (ANL) reveals how market expectations are adjusting under pressure from competition by pharma behemoths and the risks of losing patent exclusivity for its primary oncology drug, buparlisib.

Perusahaan pesaing

Pangali Forward P/E ONC|HALO (Halozyme Inc.) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E RVMD (revmed.com)|AAPG - Prakiraan rega marang bathi|CGON: Prakiraan rega marang bathi|URGN - Pangali Forward P/E|Bicara Bio (BCAX) - Rega marang bathi mangsa ngarep|Personalis Corp - Pangali mangsa ngarep rega marang bathi|ERAS (Erasca Inc) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Delcath Systems, Inc. DCTH|Prakiraan rega marang bathi YMAB (Y-mAbs Corp)|Pangali Forward P/E Aura Bio (AURA)|Pangali Forward P/E CADL (Candel Therapeutics Inc.)|ARAY - Prakiraan rega marang bathi|SLS - Rega marang bathi mangsa ngarep|Actuate Therapeutics - Rasio kapitalisasi marang bathi mangsa ngarep|CTOR: Pangali Forward P/E|TuHURA (HURA) - Pangali Forward P/E|TARA (Protara Therapeutics Inc) - Pangali Forward P/E|FATE: Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E WHWK|TCRX (TScan) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Champions Oncology, Inc. CSBR|XBIT - Prakiraan rega marang bathi|CEL-SCI - Pangali Forward P/E|OSTX - Pangali Forward P/E|Radiopharm Theranostics Limited (RADX) - Rega marang bathi mangsa ngarep|ARTV - Kapitalisasi marang proyeksi bathi|Prakiraan rega marang bathi VERU|TPST: Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep xiliotx.com (XLO)|Renovaro - Rasio rega marang bathi mangsa ngarep|Rega marang bathi mangsa ngarep Mural Oncology MURA|KAPA - Prakiraan rega marang bathi|OKUR - Rega marang bathi mangsa ngarep|GDTC - Pangali Forward P/E|Curis, Inc. (CRIS) - Rega marang bathi mangsa ngarep|Prakiraan rega marang bathi Apollomics, Inc.|Prakiraan rega marang bathi THAR|Rasio rega marang bathi mangsa ngarep ADVB (Advanced Biomed)|Prakiraan rega marang bathi GNPX (Genprex, Inc)|CLDI: Rasio rega marang bathi sing dikarepake|Rega marang bathi mangsa ngarep sunshinebiopharma.com SBFM|XBIO - Prakiraan rega marang bathi|SLRX: Prakiraan rega marang bathi|Purple Biotech - Rasio kapitalisasi marang bathi mangsa ngarep|American Oncology Network (AONC) - Rega marang bathi mangsa ngarep|Rasio rega marang bathi mangsa ngarep BGNE|Prakiraan rega marang bathi CKPT|Rega marang bathi mangsa ngarep ELEV|Pangali Forward P/E ICAD|Pangali Forward P/E Ikena Oncology Inc. (IKNA)|Pangali Forward P/E NTBL (Notable Labs Ltd)|Kapitalisasi marang proyeksi bathi Viracta Therapeutics (VIRX)|MOR: Prakiraan rega marang bathi|NAYA (NAYA Bio) - Rasio rega marang bathi mangsa ngarep|AAPGV: Pangali Forward P/E